Jun 5, 2026 07:00AM
Jun 4, 2026 07:00AM
Jun 2, 2026 07:00AM
May 15, 2026 07:00AM
May 8, 2026 04:05PM
May 5, 2026 07:00AM
Apr 29, 2026 07:00AM Ocular Therapeutix enrolls first patient in SOL-X extension trial
Apr 29, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 27, 2026 07:00AM
Apr 22, 2026 07:00AM
Apr 19, 2026 10:00AM
Apr 14, 2026 07:00AM
Apr 13, 2026 07:01AM Ocular Therapeutix reports additional week 52 data from wet AMD trial
Apr 13, 2026 07:00AM
Apr 1, 2026 07:00AM
Mar 9, 2026 04:01PM
Feb 24, 2026 07:00AM
Feb 23, 2026 07:00AM
Feb 20, 2026 07:53AM
Feb 19, 2026 02:01PM FDA policy 'suportive' of Ocular Therapeutix (OCUL) Axpaxli NDA Submission on SOL-1 Alon - Raymond James
Feb 17, 2026 07:02AM
Feb 17, 2026 07:00AM
Feb 13, 2026 05:00PM
Feb 13, 2026 05:00PM
Feb 6, 2026 04:01PM
Feb 5, 2026 08:55AM
Feb 5, 2026 07:00AM Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Jan 23, 2026 04:01PM
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM
Dec 9, 2025 04:00AM
Dec 8, 2025 07:02AM
Dec 8, 2025 07:00AM
Dec 8, 2025 06:46AM Ocular Therapeutix (OCUL) PT Raised to $21 at H.C. Wainwright
Dec 8, 2025 05:08AM
Dec 8, 2025 04:34AM
Dec 5, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 7, 2025 07:00AM Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2025 07:05AM
Nov 4, 2025 07:02AM
Nov 4, 2025 07:00AM
Oct 28, 2025 07:00AM
Oct 8, 2025 06:45AM
Oct 7, 2025 07:00AM
Sep 30, 2025 07:08AM Ocular Therapeutix prices $475 million stock offering at $12.53 per share
Sep 30, 2025 07:08AM

323,150 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All